Recent Advances on Ultrasound Contrast Agents for Blood-Brain Barrier Opening with Focused Ultrasound
November 21, 2020 — Pharmaceutics – Special Issue: Advances in Physics Methods for Drug Delivery
The blood-brain barrier is the primary obstacle to efficient intracerebral drug delivery. Focused ultrasound, in conjunction with microbubbles, is a targeted and non-invasive way to disrupt the blood-brain barrier. Many commercially available ultrasound contrast agents and agents specifically designed for therapeutic purposes have been investigated in ultrasound-mediated blood-brain barrier opening studies. The new generation of sono-sensitive agents, such as liquid-core droplets, can also potentially disrupt the blood-brain barrier after their ultrasound-induced vaporization. In this review, we describe the different compositions of agents used for ultrasound-mediated blood-brain barrier opening in recent studies, and we discuss the challenges of the past five years related to the optimal formulation of agents.
Figure 1.: Schematic representation of several mechanisms of B BB disruption: Stable cavitation push- (a) and- pull (b) mechanism and microsteaming (c), which can permeabilize the blood-brain barrier safely. Inertial cavitaton induces micro-jetting (d), fragmentation (e), and shock-wave (f) that can permeabilize the BBB with risks of damages.
By Ambre Dauba 1; Anthony Delalande 2; Hermes A. S. Kamimura 3; Allegra Conti 4; Benoit Larrat 5; Nicolas Tsapis 6; Anthony Novell 1
1 Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 91401 Orsay, France; 2 Centre de Biophysique Moléculaire and Université d’Orléans, CNRS-UPR 4301, 45071 Orléans, France; 3 Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA; 4 Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy; 5 Université Paris-Saclay, CEA, CNRS, Baobab, NeuroSpin, 91191 Gif-sur-Yvette, France; 6 Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296 Châtenay-Malabry, France
Read full text at: Pharmaceutics 2020, 12(11), 1125; https://doi.org/10.3390/pharmaceutics12111125